{"id":29,"date":"2021-09-09T13:00:28","date_gmt":"2021-09-09T13:00:28","guid":{"rendered":"https:\/\/wp.media.unc.edu\/bupe\/?page_id=29"},"modified":"2024-06-14T14:58:52","modified_gmt":"2024-06-14T14:58:52","slug":"resources","status":"publish","type":"page","link":"https:\/\/wp.media.unc.edu\/bupe\/resources\/","title":{"rendered":"Resources"},"content":{"rendered":"<div class=\"\"><ul class=\"nav nav-tabs\" id=\"oscitas-tabs-0\"><li class=\"active\"><a class=\"\" href=\"#pane-0-0\" data-toggle=\"tab\">Table of Contents<\/a><\/li><li class=\"\"><a class=\"\" href=\"#pane-0-1\" data-toggle=\"tab\">B.U.P.E. References<\/a><\/li><li class=\"\"><a class=\"\" href=\"#pane-0-2\" data-toggle=\"tab\">About this Course<\/a><\/li><\/ul><div class=\"tab-content\"><div class=\"tab-pane active\" id=\"pane-0-0\"><div class=\"panel-group \" id=\"oscitas-accordion-0\">        <div class=\"panel panel-default\">\n            <div class=\"panel-heading\">\n              <h4 class=\"panel-title\">\n                <a class=\"accordion-toggle collapsed\" data-toggle=\"collapse\"\n                data-parent=\"#oscitas-accordion-0\"\n                href=\"#details-0-0\">\n                Buprenorphine Facts\n                <\/a>\n              <\/h4>\n            <\/div>\n            <div id=\"details-0-0\" class=\"panel-collapse collapse \">\n              <div class=\"panel-body\">\r\n<ul>\r\n<li aria-level=\"1\" aria-checked=\"false\"><a href=\"https:\/\/wp.media.unc.edu\/bupe\/wp-content\/uploads\/sites\/16\/2021\/11\/Bupe-Formulations.pdf\">Bupe formulation chart<\/a><\/li>\r\n<\/ul>\r\n<\/div>\n            <\/div>\n        <\/div>        <div class=\"panel panel-default\">\n            <div class=\"panel-heading\">\n              <h4 class=\"panel-title\">\n                <a class=\"accordion-toggle collapsed\" data-toggle=\"collapse\"\n                data-parent=\"#oscitas-accordion-0\"\n                href=\"#details-0-1\">\n                Role of Pharmacists\n                <\/a>\n              <\/h4>\n            <\/div>\n            <div id=\"details-0-1\" class=\"panel-collapse collapse \">\n              <div class=\"panel-body\">\r\n<ul>\r\n<li><a href=\"https:\/\/wp.media.unc.edu\/bupe\/wp-content\/uploads\/sites\/16\/2021\/11\/Suggestions-for-topics-to-discuss-with-patients-prescribed-buprenorphine-products_v2.pdf\" rel=\"noopener\">Suggestions for topics to discuss with patients who have been prescribed buprenorphine products<\/a><\/li>\r\n<\/ul>\r\n<\/div>\n            <\/div>\n        <\/div>        <div class=\"panel panel-default\">\n            <div class=\"panel-heading\">\n              <h4 class=\"panel-title\">\n                <a class=\"accordion-toggle collapsed\" data-toggle=\"collapse\"\n                data-parent=\"#oscitas-accordion-0\"\n                href=\"#details-0-2\">\n                Overcoming Barriers\n                <\/a>\n              <\/h4>\n            <\/div>\n            <div id=\"details-0-2\" class=\"panel-collapse collapse \">\n              <div class=\"panel-body\">\r\n<ul>\r\n<li><a href=\"https:\/\/wp.media.unc.edu\/bupe\/wp-content\/uploads\/sites\/16\/2021\/11\/overcoming_barriers_quiz.pdf\">Barriers facing patients with opioid use disorder: quiz with correct answers<\/a><\/li>\r\n<\/ul>\r\n<\/div>\n            <\/div>\n        <\/div>        <div class=\"panel panel-default\">\n            <div class=\"panel-heading\">\n              <h4 class=\"panel-title\">\n                <a class=\"accordion-toggle collapsed\" data-toggle=\"collapse\"\n                data-parent=\"#oscitas-accordion-0\"\n                href=\"#details-0-3\">\n                Communication and Other Tools\n                <\/a>\n              <\/h4>\n            <\/div>\n            <div id=\"details-0-3\" class=\"panel-collapse collapse \">\n              <div class=\"panel-body\">\r\n<ul>\r\n<li style=\"list-style-type: none;\">\r\n<\/li>\r\n<li><a href=\"https:\/\/wp.media.unc.edu\/bupe\/wp-content\/uploads\/sites\/16\/2021\/11\/DEA-regulatory-constraints-and-order-size-information.pdf\">DEA regulatory constraints and order size information<\/a><\/li>\r\n<li><a href=\"https:\/\/wp.media.unc.edu\/bupe\/wp-content\/uploads\/sites\/16\/2024\/06\/comm_templates_for_pharmacists.pdf\">Communication templates with prescribers and wholesalers<\/a><\/li>\r\n<li><a href=\"https:\/\/wp.media.unc.edu\/bupe\/wp-content\/uploads\/sites\/16\/2021\/11\/SAMPLE-Memorandum-of-Agreement-dedicated-dispensing.pdf\">Sample pharmacy MOU with prescribing entity<\/a><\/li>\r\n<\/ul>\r\n<\/div>\n            <\/div>\n        <\/div>        <div class=\"panel panel-default\">\n            <div class=\"panel-heading\">\n              <h4 class=\"panel-title\">\n                <a class=\"accordion-toggle collapsed\" data-toggle=\"collapse\"\n                data-parent=\"#oscitas-accordion-0\"\n                href=\"#details-0-4\">\n                Other Resources\n                <\/a>\n              <\/h4>\n            <\/div>\n            <div id=\"details-0-4\" class=\"panel-collapse collapse \">\n              <div class=\"panel-body\">\r\n<ul>\r\n<li><a href=\"https:\/\/wp.media.unc.edu\/bupe\/wp-content\/uploads\/sites\/16\/2021\/11\/Resources-for-helping-patients-struggling-to-pay-for-buprenorphine-products.pdf\">Resources for helping patients struggling to pay for buprenorphine products<\/a><\/li>\r\n<li><a href=\"https:\/\/wp.media.unc.edu\/bupe\/wp-content\/uploads\/sites\/16\/2021\/11\/Naloxone-resources.pdf\">Naloxone resources<\/a><\/li>\r\n<li><a href=\"https:\/\/wp.media.unc.edu\/bupe\/wp-content\/uploads\/sites\/16\/2024\/06\/other_resources_june_24.pdf\">Other harm reduction resources<\/a><\/li>\r\n<li>Liability Insurance<\/li>\r\n<li>North Carolina DEA field office phone numbers<\/li>\r\n<ul>\r\n    <li>The investigative DEA field office can be useful to answer questions about what to do with suspicious prescriptions, however these field offices would not be useful for information regarding registration issues. <\/li>\r\n    <li>Greensboro: 571-362-4219<\/li>\r\n    <li>Raleigh: 571-362-0687<\/li>\r\n    <li><a href=\"https:\/\/deadiversion.usdoj.gov\" target=\"_blank\" rel=\"noopener\">Website<\/a><\/li>\r\n<\/ul>\r\n<\/ul>\r\n<\/div>\n            <\/div>\n        <\/div><\/div><\/div><div class=\"tab-pane \" id=\"pane-0-1\"><ol>\r\n    <li>SAMHSA. TIP 63: Medications for Opioid Use Disorder. Published online 2021. Accessed August 1, 2021. <a href=\"https:\/\/store.samhsa.gov\/product\/TIP-63-Medications-for-Opioid-Use-Disorder-Full-Document\/PEP21-02-01-002\">https:\/\/store.samhsa.gov\/product\/TIP-63-Medications-for-Opioid-Use-Disorder-Full-Document\/PEP21-02-01-002<\/a><\/li>\r\n    <li>Carroll J, Green T, Noonan R. <em>Evidence-Based Strategies for Preventing Opioid Overdose: What\u2019s Working in the United States, 2018<\/em>. Centers for Disease Control; 2018:40. Accessed December 2, 2019. <a href=\"https:\/\/www.cdc.gov\/drugoverdose\/pdf\/pubs\/2018-evidence-based-strategies.pdf\">https:\/\/www.cdc.gov\/drugoverdose\/pdf\/pubs\/2018-evidence-based-strategies.pdf<\/a><\/li>\r\n    <li>Providers Clinical Support System. MAT Waiver Training for MD\/DOs to Prescribe buprenorphine. Providers Clinical Support System. Accessed August 27, 2021. <a href=\"https:\/\/pcssnow.org\/medications-for-opioid-use-disorder\/waiver-training-for-physicians\/\">https:\/\/pcssnow.org\/medications-for-opioid-use-disorder\/waiver-training-for-physicians\/<\/a><\/li>\r\n    <li>Chilcoat HD, Amick HR, Sherwood MR, Dunn KE. Buprenorphine in the United States: Motives for abuse, misuse, and diversion. <em>Journal of Substance Abuse Treatment<\/em>. 2019;104:148-157. doi:10.1016\/j.jsat.2019.07.005<\/li>\r\n    <li>Cicero TJ, Ellis MS, Chilcoat HD. Understanding the use of diverted buprenorphine. <em>Drug and Alcohol Dependence<\/em>. 2018;193:117-123. doi:10.1016\/j.drugalcdep.2018.09.007<\/li>\r\n    <li>Dart RC. Per A New Frontier: Prescription Drug Abuse Beyond Opioids. Presented at: Researched Abuse, Diversion and Addiction-Related Surveillance (RADARS) System 2020 14th Annual Scientific Meeting; n.d.<\/li>\r\n    <li>Carroll JJ, Rich JD, Green TC. The More Things Change: Buprenorphine\/naloxone Diversion Continues While Treatment Remains Inaccessible. <em>J Addict Med<\/em>. 2018;12(6):459-465. doi:10.1097\/ADM.0000000000000436<\/li>\r\n    <li>Monico LB, Mitchell SG, Gryczynski J, et al. Prior Experience with Non-Prescribed Buprenorphine: Role in Treatment Entry and Retention. <em>Journal of Substance Abuse Treatment<\/em>. 2015;57:57-62. doi:10.1016\/j.jsat.2015.04.010<\/li>\r\n    <li>The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update. <em>Journal of Addiction Medicine<\/em>. 2020;14(2S):1-91. doi:10.1097\/ADM.0000000000000633<\/li>\r\n    <li>Linke S, Harrison R, Wallace P. A Web-based intervention used in general practice for people with excessive alcohol consumption. <em>J Telemed Telecare<\/em>. 2005;11 Suppl 1:39-41. doi:10.1258\/1357633054461895<\/li>\r\n    <li>Debelak K, Morrone WR, O\u2019grady KE, Jones HE. Buprenorphine+ naloxone in the treatment of opioid dependence during pregnancy\u2014initial patient care and outcome data. <em>The American journal on addictions<\/em>. 2013;22(3):252-254.<\/li>\r\n    <li>Project CARA. Use of Buprenorphine -Naloxone in Pregnancy (Project CARA Brief). Published online 2021.<\/li>\r\n    <li>Strickland DM, Burson JK. Sublingual absorption of naloxone in a large clinical population. <em>J Drug Metab Toxicol<\/em>. 2018;9(02):240.<\/li>\r\n    <li>Blazes CK, Morrow JD. Reconsidering the usefulness of adding naloxone to buprenorphine. <em>Frontiers in Psychiatry<\/em>. 2020;11:958.<\/li>\r\n    <li>Health and Human Services. Practice Guidelines for the Administration of Buprenorphine for Treating Opioid Use Disorder. Published online April 28, 2021. Accessed September 10, 2021. <a href=\"https:\/\/www.federalregister.gov\/documents\/2021\/04\/28\/2021-08961\/practice-guidelines-for-the-administration-of-buprenorphine-for-treating-opioid-use-disorder\">https:\/\/www.federalregister.gov\/documents\/2021\/04\/28\/2021-08961\/practice-guidelines-for-the-administration-of-buprenorphine-for-treating-opioid-use-disorder<\/a><\/li>\r\n    <li>Pattani A. DEA takes aggressive stance toward pharmacies trying to dispense addiction medicine. <em>NPR<\/em>. <a href=\"https:\/\/www.npr.org\/sections\/health-shots\/2021\/11\/08\/1053579556\/dea-suboxone-subutex-pharmacies-addiction\">https:\/\/www.npr.org\/sections\/health-shots\/2021\/11\/08\/1053579556\/dea-suboxone-subutex-pharmacies-addiction<\/a>. Published November 8, 2021.<\/li>\r\n    <li>Williams AR, Samples H, Crystal S, Olfson M. Acute care, prescription opioid use, and overdose following discontinuation of long-term buprenorphine treatment for opioid use disorder. <em>American Journal of Psychiatry<\/em>. 2020;177(2):117-124.<\/li>\r\n    <li>Davoli M, Perucci CA, Forastiere F, et al. Risk factors for overdose mortality: a case-control study within a cohort of intravenous drug users. <em>International Journal of Epidemiology<\/em>. 1993;22(2):273-277.<\/li>\r\n    <li>O\u2019Halloran C, Cullen K, Njoroge J, et al. The extent of and factors associated with self-reported overdose and self-reported receipt of naloxone among people who inject drugs (PWID) in England, Wales and Northern Ireland. <em>International Journal of Drug Policy<\/em>. 2017;46:34-40. doi:10.1016\/j.drugpo.2017.05.017<\/li>\r\n    <li>Flavin L, Malowney M, Patel N, et al. Availability of Buprenorphine Treatment in the 10 States With the Highest Drug Overdose Death Rates in the United States. <em>Journal of Psychiatric Practice<\/em>. 2020;26(1):17-22.<\/li>\r\n    <li>Ma J, Bao YP, Wang RJ, et al. Effects of medication-assisted treatment on mortality among opioids users: a systematic review and meta-analysis. <em>Mol Psychiatry<\/em>. 2019;24(12):1868-1883. doi:10.1038\/s41380-018-0094-5<\/li>\r\n    <li>American Pharmacists Association. <em>Increasing Access to and Advocacy for Medications for Opioid Use Disorder (MOUD)<\/em>. 2020. Accessed August 10, 2020. <a href=\"https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC7440871\/\">https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC7440871\/<\/a><\/li>\r\n    <li>NC Legislature. <em>STOP Act<\/em>. 2017. <a href=\"http:\/\/www.ncbop.org\/PDF\/NCDHHSImplementationofCSRSSTOPActJuly2021.pdf\">http:\/\/www.ncbop.org\/PDF\/NCDHHSImplementationofCSRSSTOPActJuly2021.pdf<\/a><\/li>\r\n    <li><a href=\"https:\/\/www.deadiversion.usdoj.gov\/pubs\/docs\/Dear_Registrant_MOUD.pdf\">https:\/\/www.deadiversion.usdoj.gov\/pubs\/docs\/Dear_Registrant_MOUD.pdf<\/a><\/li>\r\n    <li><a href=\"https:\/\/www.ncdhhs.gov\/sl-2017-57-section-11f10-opioid-prescription-drug-abuse-monitoring-annual-report-1\/open\">https:\/\/www.ncdhhs.gov\/sl-2017-57-section-11f10-opioid-prescription-drug-abuse-monitoring-annual-report-1\/open<\/a><\/li>\r\n    <li><a href=\"https:\/\/www.nih.gov\/news-events\/news-releases\/telehealth-supports-retention-treatment-opioid-use-disorder\">https:\/\/www.nih.gov\/news-events\/news-releases\/telehealth-supports-retention-treatment-opioid-use-disorder<\/a><\/li>\r\n    <li>The American Society of Addiction Medicine. Advancing Access to Addiction Medications. Accessed May 11, 2017.<\/li>\r\n    <li><a href=\"https:\/\/www.deadiversion.usdoj.gov\/pubs\/docs\/A-23-0020-Dear-Registrant-Letter-Signed.pdf\">https:\/\/www.deadiversion.usdoj.gov\/pubs\/docs\/A-23-0020-Dear-Registrant-Letter-Signed.pdf<\/a><\/li>\r\n<\/ol><\/div><div class=\"tab-pane \" id=\"pane-0-2\"><p>The development of <b><i>B<\/i><\/b><i>uprenorphine <\/i><b><i>U<\/i><\/b><i>nderstanding in the <\/i><b><i>P<\/i><\/b><i>harmacy <\/i><b><i>E<\/i><\/b><i>nvironment (B.U.P.E.)<\/i> was supported by the University of North Carolina Eshelman School of Pharmacy and RTI International. The content is solely the responsibility of the authors and does not necessarily represent the official views of the funders.<\/p>\r\n<p>The Continuing Education program is a grant-funded effort that teaches pharmacists about dispensing of buprenorphine for patients with opioid use disorder (OUD) at community pharmacies. Content focuses on what buprenorphine is; factors that have led to an increase in buprenorphine prescriptions; barriers that can limit access to buprenorphine at community pharmacies; and how to overcome these barriers.<\/p>\r\n<p>Program content was developed by Bayla Ostrach, MA, PhD, CIP and Delesha Carpenter, PhD, MSPH, with Grace Trull, BS. A team of expert stakeholders with relevant experience helped develop the program content. The Development Panel included community pharmacists and stakeholders involved in pharmacist education and rural healthcare.<\/p>\r\n<p>The program was produced by the<a href=\"https:\/\/faopharmacy.unc.edu\/media\/\"> MEDIA<\/a> team at the UNC Eshelman School of Pharmacy.<\/p><\/div><\/div><\/div>\r\n<div class=\"lowernav\"><a href=\"\/bupe\/examples-faqs\/\"><button class=\"navbtn prev\" type=\"button\">\u2190 back<\/button><\/a><a href=\"#\"><button class=\"navbtn top\" type=\"button\">top<\/button><\/a><\/div>\r\n\r\n\r\n<p><\/p>\r\n\r\n","protected":false},"excerpt":{"rendered":"\u2190 backtop","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"_links":{"self":[{"href":"https:\/\/wp.media.unc.edu\/bupe\/wp-json\/wp\/v2\/pages\/29"}],"collection":[{"href":"https:\/\/wp.media.unc.edu\/bupe\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/wp.media.unc.edu\/bupe\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/wp.media.unc.edu\/bupe\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/wp.media.unc.edu\/bupe\/wp-json\/wp\/v2\/comments?post=29"}],"version-history":[{"count":72,"href":"https:\/\/wp.media.unc.edu\/bupe\/wp-json\/wp\/v2\/pages\/29\/revisions"}],"predecessor-version":[{"id":1639,"href":"https:\/\/wp.media.unc.edu\/bupe\/wp-json\/wp\/v2\/pages\/29\/revisions\/1639"}],"wp:attachment":[{"href":"https:\/\/wp.media.unc.edu\/bupe\/wp-json\/wp\/v2\/media?parent=29"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}